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7 Medical treatments of neuron-related disorders are limited due to the difficulty of targeting 
8 brain cells. Major drawbacks are the presence of the blood-brain barrier and the lack of 
9 specificity of the drugs for the diseased cells. Nanomedicine-based approaches provide 
10 promising opportunities for overcoming these limitations. Although many previous reviews are 
11 focused on brain targeting with nanomedicines in general, none of those are concerned 
12 explicitly on the neurons, while, targeting neuronal cells in central nervous diseases is now one 
13 of the biggest challenges in nanomedicine and neuroscience. We review the most relevant 
14 advances in nanomedicine design and strategies for neuronal drug delivery that might 
15 successfully bridge the gap between laboratory and bedside treatment in neurology.
16
17 Keywords: nanoparticles; targeted drug delivery; brain and neuron targeting; neuron-related 
18 diseases
































































19 1. Introduction 
20 At this moment, many neuron-related diseases (e.g., neurodegenerative diseases, 
21 neuroendocrine disorders) are not adequately treated due to the lack of approaches to effectively 
22 reach the targets on specific neuronal populations. These central nervous system (CNS) 
23 pathologies have led to devastating implications on the human public health, since low 
24 availability or side effects of the drugs (e.g., due to unspecific delivery in other cells or tissues) 
25 limit the clinical effectiveness against the neuron-related disease. The difficulty in achieving 
26 improved clinical outcomes for CNS disorders relies on the inability to deliver therapeutically 
27 relevant doses of the therapeutic to diseased cells or regions [1–3]. One of the main obstacles 
28 for the delivery of systemically administered therapies into the brain is the Blood-Brain Barrier 
29 (BBB). Besides this barrier, exposure of the drug to cells or tissues out of the target cell implies 
30 side effects, toxicity, and loss of effectiveness of the therapy. Finally, chemical instability of 
31 potential drugs against neuronal diseases limits their use and claims the use of carriers 
32 protecting the drug until the delivery in the brain cells. 
33 Nanomedicine-based approaches provide promising opportunities for overcoming these 
34 limitations and therefore improve the therapeutic efficacy of neuron-related diseases. The use of 
35 nanoparticles (NPs) as drug delivery carriers has been widely investigated in pre-clinical 
36 investigations and is now being applied in the clinical settings for selected CNS diseases [1,4–7] 
37 (Table1). These studies demonstrate that the use of different types of nanoformulations 
38 significantly overcomes the BBB crossing and improves CNS pharmacokinetic and distribution 
39 in brain areas in comparison to free drug [8,9]. In addition to overcoming BBB, surface 
40 decoration with specific ligands would allow “active targeting” to a brain cell type [10]. At this 
41 time, targeting neuronal cells in CNS pathologies remains one of the biggest challenges in 
42 nanomedicine and neuroscience.
43 Concerning the clinical application of nanoformulations targeting neuronal diseases, there is a 
44 clear gap between laboratory and bedside treatment. Currently, there are only a few 
45 nanomedicines already in clinical use and in the clinical pipeline to treat neurodegenerative 
46 disorders (Table 1). These nanomedicines are mainly based on the use of polymeric-based 
47 therapeutics, gold nanocrystals, and curcumin encapsulated in nano-micelles and nanoparticles 
48 of an inhibitor of alpha-secretase in Alzheimer’s disease (AD) (APH-1105). However, these 
49 nanoformulations were not specifically designed to target neurons, and the mechanistic aspects 
50 and the plausible modifications to improve their clinical outcome are still poorly known. A 
51 major factor for the low number of nanomedicines to target neuronal diseases in clinical trials is 
52 the complexity of the design and development of these approaches, and thereby an exhaustive 
53 preclinical validation is required. Therefore, in the last years many efforts have been focused on 
54 the development and testing of neuronal-targeting nanomedicines in models of CNS disorders 
55 (particularly rodents) that could improve the clinical application of these nanoparticles into 
56 neurology.   
57 In this review, we will describe the main nanomedicine-based approaches implemented to reach 
58 neurons and thereby treat CNS disorders. We will discuss the most recent advances on 
59 nanomedicine design, type of nanocarriers, therapeutic cargos, as well as strategies to target 
60 neurons in the treatment of neuronal diseases in vivo. A brief description on the hurdles in brain 
61 delivery is also included. Although previous reviews are focused on brain targeting with 
62 nanomedicines in general, none of them are concerned explicitly on the neurons. This review 
63 highlights some interesting evidence that might successfully bridge the gap between laboratory 
64 and bedside treatments.
































































65 2. The hurdles in brain delivery strategies 
66 The brain vasculature plays a crucial role as a barrier, transport, and distribution of 
67 micronutrients, macronutrients and oxygen to the CNS and CNS homeostasis. BBB is 
68 composed of specialized endothelial cells with specific properties that restrict the free 
69 movement of molecules, ions, and cells from blood to CNS. Besides, these endothelial cells 
70 facilitate the transport of toxic products from CNS to the blood. Both processes are critical for 
71 proper neuronal function and the protection of CNS from pathogens, toxins, inflammation, and 
72 diseases. Additional cells, such as neuroglial cells (astrocytes), pericytes, and neurons, and a 
73 discontinuous basal membrane, play a key role in the function and the maintenance of the BBB 
74 properties (Fig. 1). The low permeability of the BBB is the major hurdle for drug delivery to 
75 brain cells.   
76 2.1. Blood-Brain Barrier 
77 Some structural features make the BBB selectively permeable. The endothelial cells of the 
78 cerebral microvessels are sealed together by tight junctions that limit the free diffusion of 
79 molecules, and ions across the BBB [11] (Fig. 1). Tight junctions are constituted by the trans 
80 membrane and cytoplasmic proteins that include claudin, occludin, junction adhesion molecules 
81 and accessory proteins involved in the formation of more adherent junctions [10]. This strong, 
82 cohesive system maintains endothelial cells tightly connected. It limits the paracellular transport 
83 (passage between endothelial cells) and also renders polarization of these endothelial cells 
84 where the luminal plasma membrane is directed towards blood. The movement between the 
85 blood and the brain is controlled through tightly regulated cellular transport (termed 
86 transcellular transport). The transcellular transport involves the passive diffusion of lipophilic 
87 molecules and transporters. There are two types of transporters: i) carrier-mediated transporters 
88 of endogenous molecules and ii) the efflux transporters. Most of the carrier-related transporters 
89 are related to the transport of nutrients, peptides, and proteins. The CNS endothelial cells 
90 express a wide variety of these nutrient transporters, such as glucose transporter-1 (GLUT-1), 
91 which is responsible for the glucose uptake and SLC16a1 for lactate and pyruvate transport. In 
92 addition, the CNS endothelial cells express several receptor-mediated transport systems, 
93 including low-density receptor-related lipoprotein (LPR)1/LPR8, transferrin receptor, and 
94 insulin receptor (extensively reviewed in [12,13]). Many of these transport systems have been 
95 explored as a possible gate for brain-directed drug delivery [14,15]. Efflux transporters are 
96 located in the luminal compartment, and they transport a wide array of molecules from CNS 
97 into the blood. They are involved in the transport of neurotoxic lipid-soluble molecules or drugs 
98 out to the brain. Inhibition of these efflux pumps have been explored as new strategies for brain 
99 targeting [16,17]. 
100 2.2. Astrocytes and pericytes
101 Astrocytes are the most abundant glial cell type in the CNS and support neuron function by 
102 regulating neurotransmitters and electrolyte balance. Astrocytes envelop the BBB endothelium, 
103 and they have cellular protrusions that cover the blood vessels and neuronal synapses, 
104 promoting a direct link between vasculature and neuronal circuits [18]. It has been described as 
105 a direct contact between the end-feet of astrocytes and the abluminal part of the CNS 
106 microvessels that greatly enhance endothelial cell tight junctions contributing to an increase in 
107 barrier integrity [19]. Besides, astrocytes express a range of proteins that control water 
108 homeostasis in the CNS and secrete factors (e.g., angiotensin-1) that play a role in the barrier 
109 properties of CNS endothelial cells [20].
































































110 Pericytes surround the CNS endothelial cells on the abluminal side and they can act as 
111 macrophages regulating proliferation, migration, differentiation, vascular branching, and 
112 survival of endothelial cells and can regulate blood-flow of capillaries [21]. Pericytes have a 
113 close physical association with CNS endothelium and are involved in the formation of gap 
114 junctions, peg-and-socket junctions [22], which makes pericytes the key cells for the BBB 
115 maintenance and stabilization and tight junctions development. 
116 Altogether, astrocytes and pericytes may play an important role in the maintenance of the BBB 
117 structure and function and BBB permeability, respectively, and therefore might be taken into 
118 consideration for effective drug delivery. 
119 2.3. Neurons
120 Neurons are major electrically excitable cells in the brain that process and transmit information 
121 to other cells through synapses. They are important therapeutic targets as they are usually 
122 impaired in most brain pathologies: stroke or traumatic brain injury, neurodegenerative diseases, 
123 psychiatric disorders and epilepsy, among others. 
124 Drug delivery specifically to neurons is challenging because i) neurons are only around 10% of 
125 all brain cells, ii) they are non-phagocytic compared to glial cells, and iii) there are different 
126 kinds of neurons with completely different functions. Since the final aim is targeting one 
127 specific group of disease-related neurons in the brain, it is of high importance to develop drug 
128 delivery strategies for targeting specifically impaired neurons to minimize drug side-effects and 
129 improve therapeutic efficiency [1]. 
130 Specific characteristics of neurons and of the NP itself can help in the design of delivery 
131 systems, particularly nanoplatforms, for targeting neurons over non-neuronal cells: 
132 i. Neuronal uptake of lipid nanoparticles (LNP) is facilitated by adsorption of ApoE 
133 secreted by astrocytes, to the NPs, which can be recognized by LDL receptors and 
134 subsequent endocytosis into neurons in vivo [23]. 
135 ii. Neurons show a high abundance of GT1b gangliosides and sphingophospholipids in 
136 their plasma membrane. Tet1 is a 12-amino acid peptide that exhibits high affinity for 
137 those molecules and has been demonstrated to bind mainly to neural progenitor cells in 
138 vivo [24].
139 iii. The nicotinic acetylcholine receptor (nAChR) and the neuronal cell adhesion molecule 
140 (NCAM) present in the plasma membrane of neurons facilitate the entry of rabies virus 
141 through the binding of a viral glycoprotein, which is responsible for the neurotrophic 
142 nature of the infection. Drug delivery systems using this glycoprotein can offer a non-
143 toxic and non-invasive approach for the targeting of neurons [25,26].
144 iv. Neurons are highly receptive to exosomes. Exosomes are extracellular vesicles involved 
145 in transmitting reciprocal signals between cells, can cross the BBB, and can be loaded 
146 with a wide range of cargos (e.g., drugs, nucleic acids, and proteins). Therefore, they 
147 are a promising tool for therapeutic delivery strategies. It has recently been shown that 
148 exosomes released by activated glutamatergic neurons bind selectively to other neurons 
149 instead of being internalized by glial cells [27,28]. The comprehension of the exosome 
150 mechanisms that drive neuron selectivity will provide new tools for specific targeting to 
151 neurons. 
152 Since these characteristics are shared by most of the neurons, neuron subtype-delivery systems 
153 must be developed for the drug internalization at diseased neurons and then minimize off-target 
154 effects. For example, neurons in cerebral cortex and hippocampus (affected by AD) highly 
































































155 express the M1 and M2 muscarinic acetylcholine receptors [29], while neurons in the striatum 
156 (affected by Parkinson’s disease, PD) highly express M4 [30]. The use of the appropriate ligand 
157 will enable selective targeting of diseased neurons [1]. 
158 A non-invasive strategy to bypass the BBB and blood cerebrospinal-fluid barrier is the 
159 intranasal delivery of drugs. In this route of administration, drugs are transported from nose to 
160 central nervous system through the olfactory and trigeminal nerves. Current evidence suggests 
161 that the perineural and perivascular spaces of these two nerves play a prominent role in drug 
162 trafficking, even though drug can also be endocytosed and travel intracellularly [31]. The 
163 combination of targeting delivery systems with the intranasal application would maximize the 
164 chance of drugs reaching the specific site of action.
165 2.4. Basement Membrane
166 The vascular basement membrane is a three-dimensional protein network situated between brain 
167 capillaries and the supportive cells. This extracellular matrix is secreted by pericytes and 
168 endothelial cells. It is predominantly composed of fibronectin, α4 and α5 laminins, tenascin, 
169 type IV collagen, heparin sulphate proteoglycans, and other glycoproteins [32]. The function of 
170 this matrix is to provide mechanical support for cell migration and attachment, playing an 
171 important role in BBB development, stability, barrier integrity, and providing also physical 
172 separation of adjacent tissues. In the context of drug delivery, it has been considered that the 
173 physical properties of the vascular basement membrane are an important hurdle to the overpass.
174 3. Nanoparticle-based delivery systems for neuronal targeting  
175 Nanomaterial based delivery approaches, which can be cooperatively termed as nanomedicines, 
176 have already been recognized as a competitive option of conventional therapies [33]. 
177 Nanomedicines, assembled from nanoscale materials ranging between one and several hundred 
178 nanometers, can load a variety of therapeutics including small molecule drugs, therapeutic 
179 proteins, genetic materials, and diagnosis modalities to deliver in the diseased site. With a 
180 unique pharmacokinetic/pharmacodynamic profile, nanomedicine delivers many 
181 pharmacological advantages over conventional therapy, such as improved bioavailability, 
182 reduced toxicity, and increased target-tissue selectivity. Today, nanomedicines are 
183 demonstrating significant potential in the clinics to treat a variety of severe health conditions, 
184 including cancers, infectious diseases, cardiac diseases, ocular diseases, and so on [34]. 
185 Although primarily in the preclinical stage, possibilities of using nanomedicine in the CNS-
186 related diseases have also been evaluated by many research groups [35]. The positive outcomes 
187 from nanomedicines in the treatment of many intractable diseases signify the persuasion of the 
188 nanomedicine-based approaches to overcome the extraordinary challenges of delivering 
189 therapeutic payloads to brain residing neurons. In this section, different types of nanomedicines 
190 (based on the structural characteristics, such as, size, shape and surface properties) (Table 2) and 
191 the main examples of in vivo efficiency on neuronal delivery, are discussed (Fig. 1).
192 3.1. Lipid-based nanomedicines
193 Liposomes, which are the most common lipid-based nanoparticles (LNPs), are vesicular drug 
194 delivery systems composed of natural and synthetic phospholipids, cholesterol, and other 
195 charged molecules, typically lipid derivatives [36]. Liposomes can entrap a variety of 
196 therapeutic entities, for example, small molecule drugs, biomacromolecules, and even inorganic 
197 materials inside its core that led to its versatile utility in drug delivery. Currently, several 
198 liposomal formulations are in the market and also many in the clinical trials for several diseases, 
199 including cancer, fungal and viral infections, pain management, genetic disorders, and other 
































































200 ailments [37,38]. Liposomal doxorubicin was the first such formulation to reach the market in 
201 1995 for clinical use in sarcoma and ovarian cancer, with several research groups currently 
202 exploring its application to neuroblastoma [39], which suggests that LNPs can be used for 
203 delivering drugs to neurons as well.
204 Among other types of LNPs, lipoplexes and nanovesicle complexes are the ones composed of 
205 cationic lipids capable of forming ionic interactions with polyanions like nucleic acids [40,41]. 
206 Thus, they can be utilized as delivery agents for therapeutic pDNA, siRNA, mRNA, and 
207 antisense oligonucleotides (ASOs). Tagalakis et al. [42] reported the preparation method of 
208 giant unilamellar vesicles from cationic lipid and phospholipids (1:1 molar ratio) through the 
209 lipid film hydration method. The vesicles were transformed into nanovesicles by the modified 
210 water-in-oil (W/O) emulsion transfer method [43], where the emulsion was suspended in an 
211 intermediate phase – a biphasic system containing the lipids dissolved in mineral oil, and an 
212 aqueous glucose solution. After centrifugation, unilamellar vesicles will be formed. These 
213 nanovesicles were then mixed with targeting peptides, and DNA or siRNA producing 
214 nanocomplex formulations ranged from 90-140 nm with an encapsulation rate of 94%. 
215 Fluorescent nanocomplexes were internalized in Neuro-2a cells and showed luciferase gene 
216 expression comparable to conventional cationic liposomes but with lower toxicity.
217 Neutral LNPs are also useful for mRNA and pDNA delivery to the cells [44]. These LNPs were 
218 prepared using tertiary amine-containing lipid derivatives that are neutral in the formulation, but 
219 upon endocytosis, the low pH inside the endosomes protonates these amines, decreasing their 
220 hydrophobicity and promoting collapse of the lipid nanoparticle. Tamaru et al. [45] delivered 
221 luciferase pDNA using this system into Neuro-2a and CAD cells. In another example, Tanaka et 
222 al. [46] delivered neutral LNP-encapsulated enhanced green fluorescent protein (eGFP) mRNA 
223 into the mouse brain. After intracerebroventricular (ICV) administration, gene expression was 
224 observed in brain tissue sections. Using MAP-2 as a neuronal marker, co-localization of the 
225 eGFP gene expression and MAP-2 was detected, indicating LNP uptake into neurons.
226 LNP-based strategy has been used for the delivery of ASOs, which have low brain accessibility, 
227 against CNS diseases. Aside from the use of liposomal methylprednisolone to modulate CNS 
228 inflammation [47], one promising target for the drug delivery approach is superoxide dismutase 
229 1 (SOD1), which is mutated in motor neurons in familial amyotrophic lateral sclerosis (ALS) 
230 [48]. Chen et al. [49] loaded SOD1 ASO into calcium phosphate nanoparticles, and then 
231 encapsulated this complex into a lipid layer. This LNP has a solid inorganic/nucleic acid core 
232 enclosed in an inner layer of dioleoylphosphatidic acid (DOPA) and an outer layer of dioleoyl-
233 3-trimethylammonium propane (DOTAP), cholesterol, and DSPE-PEG2000 
234 (distearoylphosphoethanolamine- polyethylene glycol 2000) The system is pH-sensitive, 
235 displaying increased disassembly at pH 5. Fluorescence-labelled particles showed time-
236 dependent cell uptake into a neuron-like NSC-34 cell line, accumulating in the cytoplasm. 
237 SOD1 levels have also been successfully knocked-down in HEK-293T cells and distributed in 
238 the brain and labeled neurons in a zebrafish model. 
239 Similar to ASO encapsulation, LNP-based strategies have been developed to encapsulate siRNA 
240 to treat neurodegenerative diseases. The use of a low molecular-weight branched 
241 polyethyleneimine (PEI) to form lipoplexes with siRNA [50] was able to reduce α-synuclein 
242 (SNCA) mRNA and protein both in vitro and in vivo, as well as demonstrate neuronal uptake. In 
243 this study, PEI lipoplexes were administered through the ICV route. However, it is unclear 
244 whether this kind of formulation can survive intravenous (IV) administration since the positive 
245 charge may cause non-specific interactions with proteins in the bloodstream. Anionic liposomes 
































































246 seem to avoid this problem. Schlich et al. [51] first prepared polyplexes with anti-SNCA siRNA 
247 and protamine, a naturally occurring protein, and then encapsulated the whole particle into 
248 anionic stealth liposomes made of distearoylphosphatidylcholine (DSPC), cholesterol, and 
249 DSPE-PEG. The negatively-charged, phospholipid-rich layer is attracted to the positively-
250 charged polyplex, which stabilizes the particle. The surface was also decorated with rabies virus 
251 glycoprotein-derived (RVG) peptide because it imparts a BBB-crossing property to the 
252 liposome.  Fluorescence-labelled LNPs showed strong signal co-localization with NeuN-
253 immunopositive primary cortical and hippocampal cells in vitro. This data is corroborated by SNCA 
254 knockdown, confirming the entry of both the LNP and cargo in neurons. 
255 3.2. Polymeric nanomedicines
256 Polymers are extensively utilized in drug delivery due to their many desirable properties, such 
257 as excellent biocompatibility, nontoxicity, feasible preparation, structural diversity, and 
258 controllable molecular architecture [52]. A variety of polymer-based therapeutics, such as 
259 polymeric drugs, polymer-drug conjugates, polymer-protein conjugates, dendrimers, polymeric 
260 micelles (PMs), and polyplexes, which can be collectively termed as polymer therapeutics, are 
261 used in a wide range of clinical applications, including cancer, autoimmune diseases, and 
262 neurological disorders [53]. An immunomodulatory polymeric drug glatiramer acetate (GA, 
263 Copaxone®), used for relapsing-remitting multiple sclerosis (RRMS), has secured its position in 
264 the US top 10 selling drugs list [53]. Multiple sclerosis (MS) is a neurodegenerative disease of 
265 the CNS symptomatically categorized as immune-mediated damage of myelin, the protective 
266 coating on nerve fibers. GA is a random polymer of glutamic acid, lysine, tyrosine, and alanine, 
267 four amino acids that are found in myelin basic protein (MBP). The molecular mass of the 
268 constituent polypeptides of GA ranges from 4.7 to 11 kDa. The mechanism of action for GA 
269 against RRMS is complex and has not been entirely interpreted, but the structural similarity of 
270 GA to MBP may allow it to act in an immunomodulating and neuroprotective fashion [54]. In 
271 addition to GA, another polymer therapeutics, Peginterferon Beta-1a (PLEGRIDY®), got FDA 
272 approval for the treatment of MS in 2014. The use of subcutaneous PEGylated (20 kDa 
273 molecular weight) interferon beta-1a offers an improved arrangement of pharmacokinetic and 
274 pharmacodynamic profiles and therapy-related side effects that leads to better patient 
275 compliance [55]. 
276 Aside from polymeric drugs and polymer drug-conjugates, PMs also exhibit high potential as 
277 nanomedicines, with various formulations under investigation in the preclinical and clinical 
278 phase for oncologic applications [56]. PMs prepared from amphiphilic block copolymers and 
279 spontaneous self-assembly processes manifest several attractive features as a preferred drug 
280 carrier. These features include a core-shell structure with the drug in the core (and thus 
281 adequately protected), a high drug loading capacity, an optimal size range of 10-100 nm in 
282 diameter and a prolonged blood circulation property, enabling tumour-specific preferential 
283 accumulation and penetration using the so-called enhanced permeability and retention (EPR) 
284 effect. The surface of polymer micelles could also be decorated with disease-specific ligands to 
285 increase its targeting ability and thus expand its therapeutic utility up until hard to reach cancers 
286 such as Glioblastoma Multiforme (GBM). GBM, the most lethal brain tumour, is nearly 
287 inaccessible to systemic therapy due to the presence of the blood-brain-tumour-barrier. 
288 Anticancer drug-loaded PMs, decorated with cyclic-Arg-Gly-Asp (cRGD) peptides that can 
289 target αvβ3- and αvβ5-integrins overexpressed in neovasculature and GBM cells [57], achieved 
290 efficient drug delivery to GBM tumours via an active transcellular pathway, bringing significant 
291 antitumour effects in a mouse model of GBM [58,59]. 
































































292 In addition to the oncologic application, the potential use of PM-type nanomedicines in other 
293 types of severe diseases, such as AD [60], sensory nerve disorders [61], and spinal cord injury 
294 [62], has also been evaluated. In these cases, polyplex micelles, formulated by self-assembly of 
295 oppositely charged PEG-polycation block copolymers and mRNA, have been utilized [63]. The 
296 core-shell structure of polyplex micelles, having the mRNA-polyamine complex in the core that 
297 is efficiently shielded by the water-soluble PEG corona, offers protection of loaded mRNA 
298 against nuclease attack, immune recognition, and aggregation in biological milieus. Intranasal 
299 administration of brain-derived neurotrophic factor (BDNF)-expressing mRNA loaded polyplex 
300 micelles enhanced the neurological recovery of olfactory function along with repairing the 
301 olfactory epithelium to an approximately typical architecture in a mouse model of 
302 experimentally induced olfactory dysfunction [61]. 
303 Lin et al [60] prepared a polyplex-micelle based delivery system consisting of PEG-poly{N-[N-
304 (2-aminoethyl)-2-aminoethyl]aspartamide}, (PEG-PAsp(DET)) and neprylisin (NEP) mRNA. 
305 NEP, a protease, degrades amyloid-β (Aβ), excessive production of which leads to neuronal 
306 death in AD. In vitro, GFP-fused NEP was expressed in Neuro2A and mouse primary neurons. 
307 NEP activity was confirmed when the Aβ introduced into the culture media was degraded. 
308 When the PMs were administered into C57/BL6J mice by ICV infusion, the GFP signals were 
309 found to co-localize with that of NeuN-marked neurons. Finally, the positive measurement of in 
310 vivo Aβ degradation verified that NEP mRNA can indeed be delivered into neurons in order to 
311 reduce concentrations of Aβ in the brain.
312 3.3. Inorganic nanomedicines
313 Compared to organic NPs, inorganic NPs are considered to be more stable and are commonly 
314 used for diagnostics and implants [64] in addition to delivery systems. They have found niche 
315 uses in biomedicine because of their inherent ability to interact with radiation. Examples of 
316 inorganic NPs include iron oxide NPs (serve as MRI contrast agents), quantum dots (substitute 
317 for fluorescent dye-loaded NPs), and materials that exhibit localized surface plasmon resonance 
318 like gold nanoparticles (used in diagnostics and plasmonic photothermal therapy) [65,66]. 
319 Due to their highly tuneable size, geometry, and surface functionality [67], the physicochemical 
320 properties of inorganic NPs can be easily modified, and the influence of these adaptable 
321 physicochemical characteristics on cell internalization and intracellular trafficking has been 
322 extensively studied against different types of cancer cells [68,69]. On the other hand, there are 
323 only a few literature reports investigating the effect of the size and shape of NPs on neurons 
324 [70]. Yet, Stojiljković et al. [71] conclusively demonstrated this when they measured the 
325 cellular uptake of gold nanoparticles (AuNPs) in differentiated (SHd) and undifferentiated 
326 (SHu) SH-SY5Y cells. AuNPs of different shapes (spheres and ovals) and sizes (15, 40, and 80 
327 nm) were prepared by reduction of gold (III) chloride using trisodium citrate. Different charges 
328 (anionic and cationic), as well as protein and lectin coatings, were introduced on the AuNP 
329 surface post-synthesis. Cellular uptake using epifluorescence and epipolarization microscopy 
330 revealed that SHu favoured the uptake of 15-nm AuNPs while 40-nm AuNPs preferentially 
331 internalized by SHd. Both cell types preferred cationic over anionic particles. SHd uptake was 
332 enhanced by coating with protein G or wheat germ agglutinin (WGA), while only protein G 
333 decoration increased uptake in SHu. While differentiation supposedly lowers mitotic activity 
334 and hence cell uptake of NPs [72], WGA recognizes the N-acetylglucosamine residues, which 
335 are abundant on the surface of SHd [73]. One of the critical features of AuNPs is its catalytic 
336 activity on the oxidation of nicotinamide adenine dinucleotide hydride (NADH) to the critical 
337 energetic co-factor, NAD+, which is an essential coenzyme involved in the production of ATP, 
































































338 the cellular energy source [74]. This critical feature of AuNPs has been utilized for the 
339 remyelination process in stable RMS therapy, as the myelin production is an energetically 
340 expensive process. Clean-surfaced, faceted gold nanocrystals (CNM-Au8) exhibited robust 
341 remyelinating activity with functionally-improved motor behaviours in mice following chronic 
342 exposure of the demyelinating agent, cuprizone, and acute exposure to another demyelinating 
343 agent lysolecithin. These gold nanocrystals function through a novel energy metabolism 
344 pathway, which involves enhancing key aerobic glycolysis indicators. A Phase 2, double-
345 blinded, randomized, placebo-controlled trial is currently underway in stable RMS due to 
346 encouraging preclinical results and the favourable safety/toxicity profiles obtained by CNM-
347 Au8 [75] (Table 1).
348 Spherical and rod-shaped fluorescent semiconductor nanocrystals, commonly known as 
349 quantum dots (QDs) or quantum rods (QRs), represents one of the most successful classes of 
350 fluorescence probes for bio-imaging facilitating investigation of intracellular processes at the 
351 single-molecule level and long-term in vivo inspection of cell trafficking, tumour targeting and 
352 diagnostics [76]. In an exciting research report, Malvindi et al., utilized asymmetric core-shell 
353 CdSe/CdS rod-shaped nanocrystals to investigate neuronal stimulation on a freshwater 
354 coelenterate, Hydra vulgaris [77]. They suggested that this neuron stimulatory effect is 
355 exclusively shape-dependent as the spherical counterpart of QRs failed to deliver the same 
356 stimulation. QRs used in this study had an average length of 35 nm with a diameter of around 4 
357 nm, whereas the diameter of the core-shell spherical nanocrystals, the QDs, was around 24 nm. 
358 While the local electric field associated with the permanent dipole moment of QRs was intense 
359 enough to induce tentacle writhing on H. vulgaris (which might have resulted from activation of 
360 neurons or nematocytes), the QDs with low internal dipole moment were unable to induce such 
361 neuronal sensory effect. In addition to shape, the surface charge of NPs also plays critical role 
362 on specific interaction of NPs with neurons. Utilizing CdSe/CdS QRs, Dante et al, demonstrated 
363 that negatively-charged NPs interact with the neuronal membrane, while NPs with a positive or 
364 neutral charge did not localize on neurons [78]. More intriguingly, this effect is independent of 
365 the size, shape, and material of NPs.  Negatively-charged NPs swiftly get localized on neuronal 
366 membranes and instigate an electrophysiological alteration. On the other hand, NPs with 
367 positive or neutral zeta-potential shows negligible nonspecific interaction with the neuronal 
368 membrane and thus induce no effects on bioelectric activity.  
369 In addition to AuNPs and QR/QD nanocrystals, mesoporous silica nanoparticles (MSNs) are 
370 inorganic NPs with promising biomedical applications. MSN size and surface functionalization 
371 are easily modifiable, aside from exhibiting biocompatibility and low toxicity. The pores used 
372 for drug loading have tuneable volumes [79]. MSNs can be synthesized by in 
373 situ polymerizations of orthosilicic acid in the presence of a base and cetyltrimethylammonium 
374 bromide as a surfactant template. Tetraethylorthosilicate is commonly used as the silica source 
375 [80]. Zhang et al. [81] prepared dopamine (DA)-decorated MSNs to deliver GSH into 
376 dopaminergic neurons. Since cells like SH-SY5Y express the DA transporter and DA receptors 
377 2 and 3 [82], DA can be used as a targeting ligand. MSNs with a rod-shaped mesoporous 
378 structure with dimensions of 180 and 120 nm were functionalized with DA through an 
379 isocyanate group on its surface. Confocal microscopy revealed increased cellular uptake of DA-
380 conjugated MSNs as compared to non-decorated MSNs. When non-dopaminergic HEK-293T 
381 cells were treated, non-specific uptake was not observed. Furthermore, pre-treatment of the cells 
382 with DA blocked the internalization of DA-conjugated MSNs, proving the concept of DA-
383 promoted uptake. 
384 3.4. Cell-derived nanomedicines-extracellular vesicles
































































385 Major extracellular vesicles (EVs), which are lipid-bound membrane vesicles secreted by cells 
386 into the extracellular space, include exosomes, microvesicles, and apoptotic bodies. Exosomes, 
387 whose size ranges approximately 50-100 nm in diameter, are secreted by exocytosis of 
388 multivesicular bodies, which are essential intermediates in endolysosomal transport [83]. These 
389 vesicles facilitate intercellular communication by carrying biologically active molecules, which 
390 are essential for cellular function [84]. Examples of cargo are mRNA and miRNA [85], and 
391 their delivery mechanisms include direct contact between surface molecules of vesicles and 
392 cells, endocytosis of vesicles, and vesicle-cell membrane fusion [83]. 
393 In a report by Oszvald et al. [84], EVs were shown to contribute to the maintenance of the 
394 intestinal stem cell niche via the delivery of EGF family members that act as niche factors. 
395 Leoni et al. [86] and colleagues further report that Annexin A1 was released as an EV 
396 component derived from intestinal epithelial cells to activate wound repair circuits. Thus, 
397 patients with active inflammatory bowel disease had elevated levels of secreted Annexin A1-
398 containing EVs in sera, which indicate their systemic distribution in response to inflammation.
399 This alteration of exosome levels in diseased conditions can be employed in active-targeted 
400 nanomedicine. Targeting the brain by neuron-specific RVG peptide-modified exosomes has 
401 been investigated to facilitate the delivery of α-synuclein-recognizing DNA aptamers into the 
402 mouse brain for PD [87]. In this technique, Lamp2b, the exosomal outer membrane protein, was 
403 engineered to fuse with the neuron-specific RVG peptide through its extra-exosomal N-
404 terminus. These exosomes were prepared by transfecting HEK-293T cells with RVG-Lamp2b 
405 plasmids and then recovering the exosomes through gradient centrifugation. The DNA aptamers 
406 were loaded by complexation with PEI and then add to the exosomes, generating 100-nm 
407 bilayer-membraned vesicles. Fluorescent exosomes were shown to be internalized into Neuro-
408 2a cells. When administered intraperitoneally (IP), the particles were able to reach the mouse 
409 brain and decrease α-synuclein aggregates in a mouse PD model. This is a prime example that 
410 surface modification of the EVs to target cells that have characteristic diseased states would be 
411 an efficient strategy in drug delivery.
412 Inorganic NP-exosome hybrids can also be prepared to take advantage of the exosomal surface 
413 for its pharmacokinetics [88]. In an important work by Perets et al [89], AuNPs were 
414 encapsulated inside bone marrow mesenchymal stem cell (MSC)-derived exosomes by 
415 incubating primary myoblasts with 5-nm AuNPs. AuNPs give the benefit of easily tracking the 
416 distribution of the MSC-derived exosomes. When administered intranasally to mice models of 
417 neurodegenerative diseases, the fluorescent exosomes gave signals which co-localized with that 
418 of NeuN-marked neurons in the pathological regions. 
419 3.5. Studies using passive or active neuronal targeting in CNS diseases
420 Most significant limitations in the therapeutic management of neurological disorders relies on 
421 the chemical instability, poor pharmacokinetics, deficient entry of the drug into the brain, and 
422 toxicity associated to the action of the therapeutics on non-neuronal cells or in peripheral tissues 
423 [4]. Besides, even though some drugs can cross BBB, their therapeutic efficacy is still limited 
424 by the lack of specific uptake by the disease-associated neurons [1]. Therefore, there is an 
425 urgent need for developing therapeutic platforms for drug delivery to treat neurological 
426 diseases. In this context, recent advances in nanotechnology have allowed the development of 
427 nanomedicines overcoming BBB in neuronal pathologies and target specific regions in the brain 
428 [1,4,10]. 
































































429 Currently, there are only a few clinical trials using nanoparticles targeting neuronal diseases 
430 (Table 1) and in these examples there is no evidence of neuronal uptake despite the therapeutic 
431 cargo provides pharmacological effects on neurons. Therefore, to improve clinical outcomes, in 
432 addition to bypassing BBB, targeting NPs against a specific population of brain cells is a major 
433 challenge. There are different approaches reported in the literature using NPs as drug-delivery 
434 system for the treatment of neuronal diseases and evidencing neuronal uptake (Fig. 1). A very 
435 common approach is loading the drug in a NP that can cross the BBB [9], by either choosing an 
436 adequate material or decorating the particle with a BBB-specific ligand, which will increase 
437 bioavailability in the brain [90]. Although not using neuron-specific ligands, this type of 
438 approach, is in some way demonstrating NP accumulation into neurons (e.g., by fluorescence 
439 microscopy) or assuming that the cargo has been released in the vicinity of the target cell by 
440 evidencing pharmacological improvement in neurons. This approach could be named as 
441 “passive neuron-targeted approaches” (Fig. 1). The most desirable and advanced strategy is the 
442 decoration of the NP with neuron-specific ligands (e.g., Tet1, RVG), thus improving the 
443 efficiency of the dose into neurons instead of other brain cell types and enhancing targeting to 
444 disease-associated neurons. These approaches using neuron-specific ligands evidence NP uptake 
445 in neurons and will be referred to as “active neuron-targeted approaches” (Fig. 1). Some of 
446 these nanoformulations could even target a specific population of neurons (Fig. 1). It is also 
447 important to highlight that, in order the bypass BBB, in the last few years, intranasal 
448 administration of brain-targeting nanoformulations is gaining importance [91,92] (Fig. 1).
449 The present section of the review is focused on reporting the most promising in vivo studies 
450 based on passive or active neuron-targeted strategies with the highest clinical prospect.  
451 3.5.1.Passive neuron-targeted approaches
452 This type of approach takes advantage of the remarkable characteristics of nanomedicines, such 
453 as increased circulation time and stability, in order to improve the chemical properties of drugs 
454 and, particularly, to boost BBB crossing and access brain cells [9]. Up to now, there are only a 
455 few examples used in humans (Table 1), and unfortunately these examples do not demonstrate 
456 specific uptake of the nanomedicine by neurons. Among these, the only clinically approved 
457 nanoformulations for neuron-related disorders are polymeric-based therapeutics indicated in the 
458 treatment of multiple sclerosis (Table 1) [53,55]. The other nanomedicines are currently under 
459 clinical trials, mainly recruiting patients for Phase 2 in case of CNM-Au8 and APH-1105 
460 nanoparticles for AD, PD, amyotrophic lateral sclerosis, and multiple sclerosis (Table 1).  
461 Apart from those clinical examples, most of the nanoformulations based on passive neuron-
462 targeted approaches are evaluated in preclinical investigations. They are mainly directed 
463 towards AD and PD therapy [2] and rely on the use of polymeric and lipid-based nanocarriers. 
464 In AD, these nanomedicines have proven very useful to improve the pharmacological efficiency 
465 of drugs with low bioavailability in the brain, poor solubility, and chemical instability. In this 
466 sense, Sánchez-López et al. [93] have recently developed PEGylated poly(lactic-co-glycolic 
467 acid) (PLGA) nanoparticles loaded with memantine, an antagonist to NMDA receptors used to 
468 treat AD. Memantine blocks NMDA receptors, decreasing the excess of glutamate that causes 
469 neuronal death. However, its clinical relevance in AD is limited due to low access to the CNS. 
470 The authors found that a NP-based formulation of memantine increases its availability in the 
471 brain, and therefore increases its effectiveness against the disease in APP/PS1 transgenic mice 
472 [93]. 
473 The use of ASO therapies has recently revealed its potential for the treatment of CNS disorders 
474 such as AD [94]. ASOs can halt the progression of the disease by neuronal gene knockdown or 
































































475 splicing modulation. Despite their low accessibility [94], ASOs have been successfully 
476 delivered to the CNS in mice model by encapsulation in  multiple glucose-installed nanocarriers 
477 capable of crossing the BBB, which can be bound to GLUT-1 expressed on brain capillary 
478 endothelial cells [95]. The controlled glucose density on the surface of the nanocarrier allows 
479 the regulation of its distribution within the brain, and it has been successfully optimized to 
480 increase the number of nanocarriers accumulating in neurons [96]. 
481 Brain-targeted nanosystem-based formulations can also be used to reduce toxicity and side 
482 effects of a drug by reducing the necessary dose. For instance, current strategies against PD are 
483 based on oral administration of dopaminergic drugs able to restore DA levels in specific areas of 
484 the brain. Nevertheless, the clinical use of these drugs relies on temporary effects with side 
485 effects, without overcoming the progression of the disease [97]. This is the case of levodopa, a 
486 precursor of DA, which is the standard treatment for PD. Polymeric NPs loaded with levodopa 
487 [98,99] or DA [100] in rodent models of PD exhibited promising results in neurobehavioral 
488 abnormalities of parkinsonian animals without undesired cardiovascular and central effects 
489 already described with the free drug [101].
490 One of the most promising therapeutic tools for neurodegenerative diseases is neurotrophic 
491 factors. Unfortunately, the crucial problems for their clinical application are their very short 
492 half-life and poor BBB crossing ability [102]. In the last few years, NPs encapsulating 
493 neurotrophic factors have been revealed as the optimal carrier to overcome BBB, protect agents 
494 from degradation, and prolong their circulation half-life [2]. Encapsulation of neuroprotective 
495 peptides like NAP in PEG-polylactide (PLA) nanoparticles, modified with B6 peptide (a 
496 transferrin substitute) acting as a specific ligand for BBB crossing, evidenced an enhanced brain 
497 and neuron delivery of NAP in vitro and in vivo mice models of AD [103]. 
498 Nose-to-brain delivery is not only a promising administration way for nanoformulations of 
499 neurotrophic factors against neurodegenerative diseases but also for the delivery of clinically 
500 relevant drugs used in epilepsy [91]. Musumeci et al. [104] recently developed oxcarbazepine 
501 loaded PLGA nanoparticles for intranasal administration. Oxcarbazepine, although approved as 
502 a first-line treatment for focal seizures, shows several secondary effects associated to its high 
503 distribution after oral administration. Intranasal administration of oxcarbazepine loaded PLGA 
504 NPs enhanced brain targeting efficiency, reduced the number of administrations compared to 
505 the free drug controlling seizures, and induced neuroprotection in rats [104]. Therefore, 
506 nanomedicine-based approaches, including intranasal formulations, evidence their potential 
507 against epilepsy [91]. 
508 Although these passive-based approaches can be clinically relevant, they still importantly rely 
509 on the ability of other brain cells to non-specifically internalize the drug or the nanocarrier 
510 leading to undesired effects and low pharmacological efficiency. 
511 3.5.2.Active neuron-targeted approaches
512 Cell-specific targeting is relevant to minimize off-target delivery and to improve the efficiency 
513 of the drug [24]. Since neuron-specific drug delivery is challenging, up to now, the number of 
514 neuron-targeted nanoformulations validated in vivo is still very low but with promising 
515 outcomes for clinical applications (Table 3). These strategies are normally based on the surface 
516 decoration of the nanocarriers with ligands expressed in neurons. Furthermore, some of these 
517 studies used a dual-targeting strategy based on co-decoration of both BBB-penetrating ligand 
518 and neuron-targeting ligand on the surface of the nanocarrier [105,106]. 
































































519 Tet1 is a 12-amino acid peptide that has been shown to bind specifically to neurons and 
520 therefore, has been used for neuron-specific binding in rodents in vivo [24]. Interestingly, Wang 
521 et al. [107] recently developed PEGylated poly(2-(N,N-dimethylamino)ethylmethacrylate) 
522 (PEG-PDMAEMA) nanocomplexes decorated with cingulin (CGN) peptide for BBB crossing 
523 and the Tet1 peptide for neuron-specific binding. The nanocomplexes formed were loaded with 
524 BACE1 siRNA. BACE1 (beta-site amyloid protein precursor cleaving enzyme 1) is a key 
525 protein necessary for the formation of Aβ plaques in AD. The use of this nanoformulation 
526 avoided siRNA degradation, achieved neuron targeting, and improved cognitive function and 
527 symptoms of AD in APP/PS1 transgenic mice [107]. A recent study from the same research 
528 group, updated this targeting strategy by developing a fusion peptide consisting on a BBB-
529 penetrating TGN peptide (a peptide with higher brain accumulation than CGN) and a neuron-
530 binding peptide Tet1, through a glycine linker to synergistically increase the BBB- and neuron 
531 targeting efficacy [106]. The TPL-NP was used for the encapsulation of NAP, which is a 
532 neuroprotective peptide whose clinical application is limited due to ineffective neuron targeting. 
533 Administration of TPL-NP loaded with NAP in AD mice significantly enhanced 
534 neuroprotection and improved cognitive performance [106].  
535 A therapeutic target for AD management is oxidative damage in mitochondria of impaired 
536 central neurons. Therefore, the specific delivery of antioxidants, such as resveratrol, to the 
537 mitochondria of diseased neurons is a challenging issue for AD treatment. To tackle this 
538 problem, Yang et al. [108] elegantly achieved specific delivery of resveratrol by developing 
539 neuronal mitochondria-targeted micelles in PEG-PLA nanocarrier co-decorated with peptide 
540 C3, which is an NCAM mimicking peptide that serves both for brain and hippocampal neuron 
541 targeting, and triphenylphosphonium (TPP) that directs the micelle to the neuronal 
542 mitochondria. The targeted micelles into neuronal mitochondrial dysfunction achieved the 
543 restoration of cognitive function as well as improvement in other typical disease markers in 
544 APP/PS1 mice model. This is a promising and novel strategy to target neuronal mitochondria in 
545 AD.
546 Another neuronal target to improve neuronal uptake of NPs is the tyrosine kinase receptor A 
547 (TrkA), which is overexpressed in more than 99% of neurons. For instance, Zhang et al. [109] 
548 developed a PEG NP modified with ApoA-1, to achieve BBB crossing by binding scavenger 
549 receptor B1, and with NL4, a peptide that simulates a nerve growth factor (NGF) domain and 
550 can bind TrkA in neurons. This NP was designed for the delivery of BACE1 siRNA in AD. The 
551 efficacy of this active neuronal targeting was first evaluated in vitro [109] and then in vivo in a 
552 mouse model of AD [110], indicating that this dual ligand combination is a promising strategy 
553 for targeting neurons in vivo. In line with this, Niu et al. [111] developed magnetic Fe3O4 NPs 
554 functionalized with oleic acid for stabilization and decorated them with NGF, which targets the 
555 TrkA, and N-isopropylacrylamide acrylic acid (NIPAm-AA) adsorbed to SNCA shRNA. 
556 NIPAm-AA is a thermoresponsive, pH-sensitive polymer, which is well-suited for drug delivery 
557 and controlled release. SNCA is a protein found in Lewy bodies, intracytoplasmic inclusions of 
558 aggregated protein that occur in PD and play an important role in the death of DA neurons in 
559 the substantia nigra. A therapeutic reduction of SNCA levels in the brain is therefore a potential 
560 target for a PD treatment. The authors demonstrated that these NPs are able to cross the BBB 
561 and target neurons to reduce SNCA expression both in vitro and in vivo [111]. 
562 Decoration of nanocarriers with lactoferrin has also been utilized for targeting diseased-neurons 
563 in PD [112,113]. Since the expression of the lactoferrin receptor is increased in dopaminergic 
564 neurons in the substantia nigra, IV administration of polymeric NPs loaded with GDNF [112] or 
































































565 urocortin [113] evidenced neuroprotection in a 6-hydroxydopamine-lesioned PD rat model. 
566 However, the specific uptake of the drugs on a subtype of neurons was not reported. 
567 The decorating ligand to target neurons may also be acting as a therapeutic drug. For instance, 
568 corticotropin-releasing factor (CRF) is a neuropeptide involved in fear and anxiety by specific 
569 activation of the CRF2 receptor. Central administration of antisauvagine-30, an antagonist of the 
570 CRF2 receptor, is promising in withdrawal anxiety [114]. Therefore, a nanoformulation based 
571 on iron oxide functionalized with (3-aminopropyl)triethoxysilane, which can readily cross the 
572 BBB, was decorated with antisauvagine-30 in order to act as a guiding peptide into the target 
573 neurons and also as the delivered drug to ameliorate anxiety-like behaviour in rats [114].
574 The use of other ligands for specific neural cell targeting such as RVG peptides [25,26], or Ts1 
575 [115] have also shown promising results. Nevertheless, these studies do not provide validations 
576 in in vivo models of the disease, when BBB and neuron expression of markers are altered. 
577 In addition to the use of surface ligands, brain- and neuron-targeted delivery could be also 
578 achieved with the use of molecules acting as penetration enhancers to neurons. A recent 
579 investigation found that in vivo co-administration of nanoliposomes with borneol elevated brain-
580 target efficiency in specific brain areas and particularly in neurons of cerebral cortex and 
581 hippocampus bypassing astrocytes [116]. The authors described how the transport pathway of 
582 borneol is providing the potential as a penetration enhancer and therefore improve neuron 
583 targeting of nanoliposomes in specific brain cells.   
584 Finally, exosomes are becoming a subject of interest in nanomedicine, due to their ability to 
585 cross the BBB, target neurons and the possibility to load different cargos [27]. Perets et al. [89] 
586 recently reported in an elegant study that MSC-derived exosomes were selectively uptaken by 
587 neuronal cells, but not glial cells, in the pathological regions of brains from animal models of 
588 CNS diseases such as AD. The migration and homing abilities of these exosomes toward 
589 specific diseased neurons could be significantly influenced by inflammatory factors, attracting 
590 the MSC-derived exosomes to lesioned areas. The authors combined AuNP labelling and CT 
591 imaging for whole-brain tracking of the exosomes in the brain after intranasal administration. 
592 This finding strengthens the possibility of using MSC-derived exosomes by intranasal 
593 administration for targeted drug delivery in diseased neurons, though, to evaluate treatment 
594 efficacy, future studies using the MSC-derived exosomes either with or without additional drug 
595 cargo are needed.
596 4. Conclusion and future perspectives 
597 In the previous sections, we have discussed several novel strategies that have been used in 
598 recent years to enhance the neuron-specific targeting of nanomedicine for different neuronal-
599 related diseases. It should be noted that most of these studies are still in the pre-clinical stage. 
600 The number of nanoformulations that are now used in humans to treat neurodegenerative 
601 disorders is very low (Table 1), and they do not provide evidence for specific brain cell-
602 targeting. Recent publications presented in this review confirm the importance of neuronal-
603 targeting to treat CNS disorders in vivo, at least in pre-clinical models of these diseases. 
604 Therefore, the progression and development of novel nanoformulations in this stage, 
605 particularly the active neuron-targeted approaches, is crucial for its clinical impact in humans. 
606 With this review, we reinforce the importance of brain cell-targeting against these diseases to 
607 bridge the bench to the bedside gap.  
608 The special pathophysiologic features of the CNS-related disorders that we elaborately 
609 discussed earlier are one of the crucial factors for this sluggish clinical progress of 
































































610 nanomedicines in the CNS-area. However, from the fundamental research point of view, 
611 additional challenges for successful bench to bedside translation of nanomedicines for CNS-
612 diseases arise, including: i) selection of a clinically relevant disease model, ii) confirmation of 
613 an administration pathway depending on the diseased area of the brain, iii) low toxicity of the 
614 nanomedicines in the healthy organs and brain areas, and finally iv) the delivery of relevant 
615 dosages of the cargo into the targeted neurons sparing the other brain cells. To overcome these 
616 challenges, many research groups are developing new nanomedicine-based approaches mainly 
617 focusing on achieving better BBB crossing and thereby therapeutic outcomes [117]. 
618 Additionally, an increasing number of studies are now developing strategies to reach neurons, 
619 even bypassing the BBB (i.e., nose-to-brain delivery) and fight against neuronal related diseases 
620 that are still unmet medical issues. In this case, the challenge is the delivery of therapeutic 
621 cargoes to brain residing neurons. Significant progress has been recently achieved for targeting 
622 neurons including the identification of the suitable nanomaterials or nanocarriers, the most 
623 appropriate BBB crossing ligands or brain delivery administration pathway and, as the biggest 
624 challenge, surface ligands able to lead the nanoformulation to a specific population of neurons, 
625 that is, an active neuron-targeted approach. In this sense, innovative strategies such as the use of 
626 dual-ligand fusion peptides to improve the brain-neuron targeting of polymeric nanocarriers 
627 [106] and development of neuronal mitochondria-targeted PMs [108] in vivo in AD, are 
628 examples of promising pre-clinical findings. Through these results, we may speculate it is only 
629 a matter of time before these active neuron-targeted approaches will be evaluated in clinical 
630 assays. In addition, the safety/toxicity profile of these nanoformulations is a crucial issue for the 
631 clinical application that is also being intensively investigated [118]. 
632 The positive outcomes prove the extraordinary ability and potential of nanomedicines for 
633 treating neuron-related pathologies in vivo, which will imply success on the clinical translation 
634 at the end. Functional collaborations between neurobiologists, materials scientists and chemists 
635 would enable a better understanding of this interdisciplinary field of “nanomedicine for neuron 
636 targeting” to identify novel targeting approaches and integrating these into nanomedicine 
637 platforms that will lead to promising and safe nanomedicine-based strategies able to reach the 
638 clinic and to overcome CNS diseases in the coming years.
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979 Figure 1. Approaches for the targeted delivery of therapeutics to diseased neurons. Brain access 
980 of the nanomedicines depends on systemic or intranasal administration. The latter pathway 
981 bypasses the Blood-Brain Barrier (BBB). Once inside the brain, if the nanoformulations are not 
982 using neuron-specific ligands but evidence release of the drug into neurons or their vicinity, in 
983 addition to other brain cells, it is referred to as “passive neuron-targeted approaches”. The most 
984 desirable strategy is the decoration of the nanoparticles with neuron-specific ligands thereby 
985 reaching neurons instead of other brain types, the so-called “active neuron-targeted 
986 approaches”, which could be non-specific or specific for a neuronal sub-population.   


































































989 • Neuron-related diseases are not adequately treated due to the lack of approaches to 
990 effectively reach the targets on specific neuronal populations.
991 • Nanomedicine-based approaches provide promising opportunities for overcoming these 
992 limitations and improving the therapeutic efficacy of central nervous diseases.
993 • Targeting neuronal cells in central nervous diseases is now one of the biggest 
994 challenges in both the nanomedicine and neuroscience field.
995 Nanomedicines for neuronal targeting
996 • Nanomedicines, including lipid-based, polymeric, inorganic nanoparticles, and 
997 exosomes, have experienced considerable advances in design and development to treat 
998 neuronal disorders.
999 • Only a few nanomedicines are currently being used in humans for treating neuronal 
1000 diseases. However these examples do not specifically demonstrate neuronal uptake even 
1001 though the therapeutic cargo provides pharmacological effects on neurons.
1002 • Towards the process of improving clinical outcomes, the development of 
1003 nanoformulations targeting a specific population of brain cells in vivo is in progress 
1004 with promising results that to be applied into clinics. 
1005 • Although both passive and active neuron targeted approaches have been studied, an 
1006 active neuron-targeted approach that is based on the use of neuron-specific ligands to 
1007 promote neuronal uptake sparing the other brain cells is the most desirable strategy. 
1008 • Novel active strategies such as the development of dual-ligand fusion peptides targeting 
1009 neurons, neuronal mitochondria-targeted nanocarriers, and intranasal administration of 
1010 exosomes selectively incorporated by neuronal cells in the pathological regions of 
1011 brains have been recently developed.
1012 Conclusion & future perspective
1013 • The development of innovative neuronal-targeting nanomedicines, particularly active 
1014 targeting-based approaches, is a critical need in the treatment of neuronal disorders, 
1015 filling the gap between laboratory and bedside treatment.
1016 • The studies discussed in this review shed light on the use of nanotechnology as a 
1017 promising strategy for specific delivery of drugs into neurons to treat neuronal-related 
1018 diseases that are still unmet clinical issues.
















































































































































































































Table 1. Nanoparticles in clinical use for the treatment of neurological disorders.
Agent Nanoformulation 
information















Multiple sclerosis FDA approved in 2014 
Amyotrophic lateral sclerosis NCT04098406 / Phase 2 






gold nanocrystals in 
sodium bicarbonate 
buffered water
Remyelination Failure in Chronic Optic 
Neuropathy In Multiple Sclerosis
NCT03536559 / Phase 2
APH-1105 
[5,119]
- Alzheimer’s disease NCT03806478 / Phase 2








Amyotrophic lateral sclerosis Iranian Registry of 
Clinical Trials number
IRCT2015062411424N3
































































Table 2. Main type of platforms used for brain delivery of therapeutics. Lipid-based, polymeric, 
inorganic, and cell-derived nanomedicines are shown, highlighting a few selected 
physicochemical characteristics focusing on neuron targeting.
Type of nanomedicine Physicochemical properties relevant for neuron 
targeting
Ref.
Liposome • Liposomes are prepared from phospholipids, for 
example dioleoyl or distearoyl 
phosphatidylcholine.




Lipoplex • Lipoplexes are prepared from cationic lipids 
having a cationic head and hydrophobic tail, for 
example, Dioleoyl-3-trimethylammonium 
propane (DOTAP).
• The size of lipoplexes varies widely, from 
couple of 100 nm to couple of μM.
[40-42]
Polymer micelle • Polymeric micelle has characteristic core-shell 
structure with optimal size range of 10-100 nm.
• While, drug or gene can be loaded inside the 
core for CNS therapy, the surface can be 





• Polymer‐protein conjugates are composite 
macromolecules derived from covalently 
combining protein and synthetic polymers. 
• PEGylated  interferon beta-1a, PLEGRIDY®, is 





Quantum rods • Semiconductor nanocrystals are made of 
CdSe/CdS.
• Rod-shaped nanocrystals, the quantum rods 
induce neuronal stimulation through its local 
electric field associated with permanent dipole 
moment. 
• Surface modifications with different functional 







• Exosomes are lipid-bound membrane vesicles 
with 50 to 100 nm in diameter.
• Structural flexibility of exosomes allows 
encapsulating AuNPs.
• With adaptable size and shape AuNPs can act as 
a support for various bio-macromolecules.
• Neuron-targeted exosomes were used to cover 
AuNPs for efficient BBB penetration. 
[83,88,89]
































































1 Table 3. Main in vivo studies using passive or active neuron-targeted nanoformulations in neurological diseases at the pre-clinical stage.
Type of 
approach
Type of NP NP-based approach and outcome Type of cargo Target disease Experimental in 
vivo model
Reference
Polymeric PEGylated PLGA nanoparticles.







Polymeric B6 peptide-modified PEG-PLA nanoparticles. 









ibotenic acid (IBO) 
coinjected mice
[103]
Polymeric Polyion complex micelle self-assembled from PEG-PLL(MPA/IM) block 
copolymer. 
The controlled glucose density on the surface of the nanocarrier allowed 
regulation of its distribution in specific brain regions. This NP also allowed ASO 








Polymeric Poly(L-lactic acid) crystalsomes [98].
The crystalsomes exhibited positive zeta potential,
nanoscale range and longer releasing time for levodopa. Enhanced effectiveness 
of the drug.
Chitosan nanoparticles [99].
Nose to brain delivery of levodopa loaded in these NPs. The NPs were 
incorporated in a thermo-reversible gel prepared using Pluronic PF127. 











Polymeric PLGA nanoparticles. 
Improved access of dopamine to the brain, lower accumulation in the periphery, 







































































Polymeric PLGA nanoparticles. 
Intranasal administration of the nanoformulation enhanced brain targeting 
efficiency, reduced the number of administrations compared to the free drug 
controlling seizures and induced neuroprotection in rats
Oxcarbazepine Epilepsy PTZ-induced 
seizures rat model
[104]
Lipid-based LNPs prepared using tertiary amine-containing lipid derivatives that are pH-
sensitive.
Neutral-surface LNPs lead to uniform gene expression in both astrocytes and 
neurons when administered through the ICV route
eGFP mRNA None ICR mice [46]
Lipid/Inorga
nic hybrid
SOD1 ASO was loaded into calcium phosphate nanoparticles, and then 
encapsulated into a lipid layer (CaP-lipid).
CaP-lipid NPs showed time and concentration dependent internalization by 
NSC-34 cells. They also diffused throughout zebrafish brain and spinal cord 
after direct injection.
SOD1 ASO Amyotrophic 
lateral sclerosis
NSC-34 motor-
neuron like cells 
and zebrafish 
[49]
Polymeric Low-MW PEI-anti-SNCA siRNA complex.
siRNA complexed with this PEI extensively distributed across the CNS down to 
the lumbar spinal cord after a single intracerebroventricular infusion. Lack of 










Polymeric PM prepared from PEG-PAsp(DET) and NEP mRNA
PM cell internalization internalization as well as NEP expression and activity 
were confirmed both in vitro in mouse neurons and in vivo in mouse
NEP mRNA Alzheimer’s 
Disease
Mice ICV injected 
with Aβ
[60] 
Polymeric PEGylated poly(2-(N,N- dimethylamino) ethyl methacrylate) (PEG-
PDMAEMA). 
Nanocomplexes decorated with cingulin (CGN) peptide for BBB crossing, and 










Inorganic Magnetic Fe3O4 nanoparticles functionalized with oleic acid for stabilization and 
decorated with NGF. 
NGF on the surface targets the Tyrosine kinase receptors overexpressed in 99% 











































































Polymeric PAMAM and PEG NP loaded with GDNF and decorated with lactoferrin. 
Expression of lactoferrin is increased in dopaminergic neurons in substantia 









Polymeric PLGA NPs loaded with urocortin and decorated with lactoferrin. 
Expression of lactoferrin is increased in dopaminergic neurons in substantia 










Iron oxide functionalized with 3-aminopropyltriethoxysilane (APTES). 
As these nanoparticles can readily cross the BBB, the only decoration added is 
antisauvagine-30, a peptide selective to corticotropin releasing factor receptor 2 
(CRF2). CRF2 mediates anxiety-like behaviour and it is a target for anxiolytic 
drugs. Therefore, ASV-30 is in this case the guiding peptide, as well as the 
delivered drug.





Exosome Neuron-specific RVG peptide-modified exosomes.
The RVG peptide was fused to the extra-exosomal N terminus of Lamp2b, to 
allow the exosomes to enter the brain efficiently. After IP administration, the 
aptamers were delivered into the neuronal cells, blocking the pathological 












Polymeric TPL-modified PEG-PLA nanoparticles (TPL-NP). 
Fusion peptide TPL comprising a BBB-penetrating peptide TGN and a neuron 







with Aβ1-42 in 
hippocampus
[106]
Polymeric Neuronal mitochondria-targeted PEG-PLA micelles (CT-NM).
CT-NM decorated with an NCAM mimetic peptide C3 for brain neuron specific 
binding and the triphenylphosphonium for mitochondrial targeting. CT-NM 







































































Exosome Mesenchymal stem cell (MSC)-derived exosomes.
The exosomes encapsulated AuNPs for easily tracking the brain distribution of 
MSC-exo after intranasal administration in mice. The MSC-exo were selectively 
uptaken by neuronal cells, but not glial cells, in the pathological regions.
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